Juncendothelial NO synthase and reactive oxygen species mediated effect of simvastatin on vessel structure and function: Pleiotropic and dose-dependent effect on tumor vascular stabilization

International Journal of Oncology

Volumn 42, Issue 4, 2013, Pages 1325-1336

  Chen, Yeshan ^a   Zhang, Sheng ^a   Peng, Gang ^a   Yu, Jing ^b   Liu, Tao ^a   Meng, Rui ^a   Li, Zhenyu ^a   Zhao, Yanxia ^a   Wu, Gang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CENTRAL HOSPITAL OF WUHAN   (China)

Author keywords

Endothelial NO synthase; Reactive oxygen species; Simvastatin; Vascular endothelial growth factor; Vascular normalization

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; VASCULOTROPIN; ANGIOGENESIS MODULATOR; ANTINEOPLASTIC AGENT; CATION; DIPHENYLIODONIUM SALT; NOS3 PROTEIN, HUMAN; SCAVENGER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; LEWIS CARCINOMA; LOW DRUG DOSE; MELANOMA; MOUSE; NONHUMAN; PERICYTE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; ANIMAL; BLOOD FLOW; C57BL MOUSE; CAPILLARY PERMEABILITY; CELL CULTURE; CELL HYPOXIA; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; ECHOGRAPHY; EXPERIMENTAL MELANOMA; METABOLISM; MICROVASCULATURE; PATHOLOGY; TUMOR VOLUME; VASCULARIZATION;

ANGIOGENESIS MODULATING AGENTS; ANIMALS; ANTINEOPLASTIC AGENTS; CAPILLARY PERMEABILITY; CARCINOMA, LEWIS LUNG; CELL HYPOXIA; CELLS, CULTURED; CISPLATIN; CYCLOPHOSPHAMIDE; DRUG SYNERGISM; FEMALE; FREE RADICAL SCAVENGERS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICROVESSELS; NITRIC OXIDE SYNTHASE TYPE III; ONIUM COMPOUNDS; REACTIVE OXYGEN SPECIES; REGIONAL BLOOD FLOW; SIMVASTATIN; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874594621     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1833     Document Type: Article

References (51)

1. Carmeliet P and Jain RK: Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10:417-427, 2011.
2. Crawford TN, Alfaro DV III, Kerrison JB and Jablon EP: Diabetic retinopathy and angiogenesis. Curr Diabetes Rev 5:8-13, 2009.
3. Fukumura D, Duda DG, Munn LL and Jain RK: Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 17:206-225, 2010.
4. Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH, Rabie T, Kaden S, Gröne HJ, Hämmerling GJ, Arnold B and Ganss R: Vascular normalization in Rgs5-defi cient tumors promotes immune destruction. Nature 453:410-414, 2008.
5. De La Cruz JP, Gonzalez-Correa JA, Guerrero A and de la Cuesta FS: Pharmacological approach to diabetic retinopathy. Diabetes Metab Res Rev 20:91-113, 2004.
6. Feng Y, vom Hagen F, Pfister F, Djokic S, Hoffmann S, Back W, Wagner P, Lin J, Deutsch U and Hammes HP: Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thromb Haemost 97:99-108, 2007.
7. Durham JT and Herman IM: Microvascular modifications in diabetic retinopathy. Curr Diab Rep 11:253-264, 2011.
8. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989, 2001.
9. Mao Y, Kiss S, Boyer JL, Hackett NR, Qiu J, Carbone A, Mezey JG, Kaminsky SM, D'Amico DJ and Crystal RG: Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab. Hum Gene Ther 22:1525-1235, 2011.
10. Zheng Z, Chen H, Wang H, Ke B, Zheng B, Li Q, Li P, Su L, Gu Q and Xu X: Improvement of retinal vascular injury in diabetic rats by statins is associated with the inhibition of mitochondrial reactive oxygen species pathway mediated by peroxisome proliferator-activated receptor γ coactivator 1α. Diabetes 59:2315-2325, 2010.
11. Li J, Wang JJ, Chen D, Mott R, Yu Q, Ma JX and Zhang SX: Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes. Exp Eye Res 89:71-78, 2009.
12. Wong WW, Dimitroulakos J, minden MD and Penn LZ: HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508-519, 2002.
13. Li J, Wang JJ, Yu Q, Chen K, Mahadev K and Zhang SX: Inhibition of reactive oxygen species by lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice role of NADPH oxidase 4. Diabetes 59:1528-1538, 2010.
14. Oliveira VN, Bessa A, Jorge ML, Oliveira RJ, de Mello MT, De Agostini GG, Jorge PT and Espindola FS: The effect of different training programs on antioxidant status, oxidative stress and metabolic control in type 2 diabetes. Appl Physiol Nutr Metab 37:334-344, 2012.
15. Woo DK, Green PD, Santos JH, D'Souza AD, Walther Z, Martin WD, Christian BE, Chandel NS and Shadel GS: Mitochondrial genome instability and ROS enhance intestinal tumorigenesis in APC (Min/+) mice. Am J Pathol 180:24-31, 2012.
16. Lin RZ, Wang TP, Hung RJ, Chuang YJ, Chien CC and Chang HY: Tumor-induced endothelial cell apoptosis: roles of NAD (P) H oxidase-derived reactive oxygen species. J Cell Physiol 226:1750-1762, 2011.
17. Deng B, Xie S, Wang J, Xia Z and Nie R: Inhibition of protein kinase Cβ2 prevents tumor necrosis factor-a-induced apoptosis and oxidative stress in endothelial cells: The role of NADPH oxidase subunits. J Vasc Res 49:144-159, 2012.
18. Kojima H, Otani A, Oishi A, Makiyama Y, Nakagawa S and Yoshimura N: Granulocyte colony-stimulating factor attenuates oxidative stress-induced apoptosis in vascular endothelial cells and exhibits functional and morphologic protective effect in oxygen-induced retinopathy. Blood 117:1091-1100, 2011.
19. Xia C, Meng Q, Liu LZ, Rojanasakul Y, Wang XR and Jiang BH: Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 67:10823-10830, 2007.
20. Weis M, Heeschen C, Glassford AJ and Cooke JP: Statins have biphasic effects on angiogenesis. Circulation 105:739-745, 2002.
21. Meda C, Plank C, Mykhaylyk O, Schmidt K and Mayer B: Effects of statins on nitric oxide/cGMP signaling in human umbilical vein endothelial cells. Pharmacol Rep 62:100-112, 2010.
22. Kashiwagi S, Izumi Y, Gohongi T, Demou ZN, Xu L, Huang PL, Buerk DG, Munn LL, Jain RK and Fukumura D: NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J Clin Invest 115:1816-1827, 2005.
23. Sadeghi MM, Collinge M, Pardi R and Bender JR: Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J Immunol 165:2712-2718, 2000.
24. Mills EM, Takeda K, Yu ZX, Ferrans V, Katagiri Y, Jiang H, Lavigne MC, Leto TL and Guroff G: Nerve growth factor treatment prevents the increase in superoxide produced by epidermal growth factor in PC12 cells. J Biol Chem 273:22165-22168, 1998.
25. Gerhardt H and Semb H: Pericytes: gatekeepers in tumour cell metastasis? J Mol Med 86:135-144, 2008.
26. Chen J, Cui X, Zacharek A and Chopp M: Increasing Ang1/Tie2 expression by simvastatin treatment induces vascular stabilization and neuroblast migration after stroke. J Cell Mol Med 13:1348-1357, 2009.
27. Vincent L, Chen W, Hong L, Mirshahi F, Mishal Z, Mirshahi-Khorassani T, Vannier JP, Soria J and Soria C: Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett 495:159-166, 2001.
28. De Bock K, Cauwenberghs S and Carmeliet P: Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 21:73-79, 2010.
29. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ and Jain RK: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-3736, 2004.
30. Rapisarda A and Melillo G: Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat 12:74-80, 2009.
31. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S and Comoglio PM: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347-361, 2003.
32. Raza A, Franklin MJ and Dudek AZ: Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 85:593-598, 2010.
33. Greenberg JI and Cheresh DA: VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Expert Opin Biol Ther 9:1347-1356, 2009.
34. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL and Jain RK: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1 and matrix metalloproteinases. Cancer Cell 6:553-563, 2004.
35. Jadeski LC and Lala PK: Nitric oxide synthase inhibition by NG-nitro-L-arginine methylester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol 155:1381-1390, 1999.
36. Ozkiris A, Erkiliç K, Koç A and Mistik S: Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy. Br J Ophthalmol 91:69-73, 2007.
37. Yu J, de Muinck ED, Zhuang Z, Drinane M, Kauser K, Rubanyi GM, Qian HS, Murata T, Escalante B and Sessa WC: Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment and blood flow reserve. Proc Natl Acad Sci USA 102:10999-11004, 2005.
38. Sata M, Nishimatsu H, Osuga J, Tanaka K, Ishizaka N, Ishibashi S, Hirata Y and Nagai R: Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 43:1214-1220, 2004.
39. Wang N, Ko SH, Chai W, Li G, Barrett EJ, Tao L, Cao W and Liu Z: Resveratrol recruits rat muscle microvasculature via a nitric oxide-dependent mechanism that is blocked by TNFα. Am J Physiol Endocrinol Metab 300:E195-E201, 2011.
40. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK and McDonald DM: Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160:985-1000, 2002.
41. Tu YT, Tao J, Liu YQ, Li Y, Huang CZ, Zhang XB and Lin Y: Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in human malignant melanoma and their relation to angiogenesis. Clin Exp Dermatol 31:413-418, 2006.
42. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62, 2005.
43. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF and Davidoff AM: Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13:3942-3950, 2007.
44. Myers AL, Williams RF, Ng CY, Hartwich JE and Davidoff AM: Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J Pediatr Surg 45:1080-1085, 2010.
45. Kohno R, Hata Y, Mochizuki Y, Arita R, Kawahara S, Kita T, Miyazaki M, Hisatomi T, Ikeda Y, Aiello LP and Ishibashi T: Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. Am J Ophthalmol 150:223-229, 2010.
46. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT and Jain RK: Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72:402-407, 2012.
47. Sharma RK, Rogojina AT and Chalam KV: Bevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF. Mol Vis 16:2175-2184, 2010.
48. Gupta A, Gupta V, Thapar S and Bhansali A: Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 137:675-682, 2004.
49. ten Kate M, van der Wal JB, Sluiter W, Hofland LJ, Jeekel J, Sonneveld P and van Eijck CH: The role of superoxide anions in the development of distant tumour recurrence. Br J Cancer 95:1497-1503, 2006.
50. Wang C, Tao W, Wang Y, Bikow J, Lu B, Keating A, Verma S, Parker TG, Han R and Wen XY: Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer. Eur Urol 58:418-426, 2010.
51. Mandal CC, Ghosh-Choudhury N, Yoneda T, Choudhury GG and Ghosh-Choudhury N: Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem 286:11314-11327, 2011.